Emerging Biotech: Partnering with Merck
Your Connection to Success

As the life science business of Merck KGaA, Darmstadt, Germany, Merck is motivated by solving the toughest problems in life science. The needs of emerging biotech companies are not foreign to us.

We serve as a strategic partner for scientists, engineers and researchers with a portfolio of more than 60,000 products. We offer a broad spectrum of proven tools and technologies for research and analytical laboratories, together with performance solutions innovations, dedicated to helping our customers succeed in the research, development and production of biotechnology and pharmaceutical drug therapies.

We provide Provantage® Services: an end-to-end capability that spans the entire development and production value chain. We work with clients who want to develop a process but either don't have capacity internally or increasingly don't want to invest in building capabilities for making clinical batches. Our facilities include a GMP facility in France where we design and develop a process with you, work on the analytical methods and validation, file the dossier and supply the clinical materials. Finally, we help transfer this process to a manufacturing facility.

What's more, we are fully committed to launching programs to help emerging biotech companies develop their molecules, via programs such as the 2014 Emerging Biotech grant program. NGM Biopharmaceuticals was the recipient, in which they were awarded products and services from Merck.

As a partner of the life science industry, EMD Millipore recognizes the impact the emerging biotech community has on the future of healthcare. We are dedicated to helping you advance your molecule by providing a range of products, services and programs.